Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: An eastern cooperative oncology group study

Robert Dreicer, Judith Manola, Bruce J. Roth, Michael B. Cohen, Alan K. Hatfield, George Wilding

Research output: Contribution to journalArticlepeer-review

90 Scopus citations

Abstract

Purpose: Cisplatin and paclitaxel are active agents in advanced urothelial cancer. A phase II trial of this combination was performed to determine the activity and toxicity of these agents in a multi-institutional setting. Patients and Methods: Fifty-two patients with advanced urothelial carcinoma were treated on one day with paclitaxel 175 mg/m2 over 3 hours followed by cisplatin 75 mg/m2, both intravenously, every 21 days. Cycles were repeated every 21 days until progression or a maximum of six cycles. Results: Twenty-six patients obtained an objective response, for an overall response rate of 50% (95% confidence interval, 36% to 64%). Four patients achieved complete clinical responses. The median overall survival time for the group was 10.6 months. Toxicity was moderate, with granulocyropenia and neurotoxicity being the most common side effects noted. Conclusion: The combination of cisplatin and paclitaxel is active in advanced urothelial cancer. Responses in visceral, nodal, and soft tissues sites were observed. Granulocytopenia without fever and grade 2/3 neuratoxicity were common. The confidence interval of the overall response rate in this study overlaps most of the other reported regimens. The optimal therapy for advanced urothelial cancer remains undefined. (C) 2000 by American Society of Clinical Oncology.

Original languageEnglish
Pages (from-to)1058-1061
Number of pages4
JournalJournal of Clinical Oncology
Volume18
Issue number5
DOIs
StatePublished - Mar 2000

Fingerprint

Dive into the research topics of 'Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: An eastern cooperative oncology group study'. Together they form a unique fingerprint.

Cite this